<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01350960</url>
  </required_header>
  <id_info>
    <org_study_id>SPC5001-901</org_study_id>
    <secondary_id>EudraCT 2011-000489-36</secondary_id>
    <nct_id>NCT01350960</nct_id>
  </id_info>
  <brief_title>Multiple Ascending Dose Study of SPC5001 in Treatment of Healthy Subjects and Subjects With FH</brief_title>
  <official_title>A First-in-Human (FIH), Randomized, Dose-Escalation, Double-Blind, Placebo-Controlled Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SPC5001 Administered to Healthy Subjects and Subjects With Familial Hypercholesterolemia (FH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Santaris Pharma A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Santaris Pharma A/S</source>
  <brief_summary>
    <textblock>
      The purpose is to study Safety and Tolerability.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability</measure>
    <time_frame>Regularly over 78 days</time_frame>
    <description>Safety evaluation will assess adverse event (AE) profile, clinical laboratory safety tests, vital signs and ECG monitoring</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak Plasma Concentration (Cmax) of SPC5001</measure>
    <time_frame>up to 78 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid lowering effect</measure>
    <time_frame>Through out the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC) of SPC5001</measure>
    <time_frame>up to 78 days</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>saline 0.9%</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5 mg/kg in Healthy Subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.5 mg/kg in Healthy subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5.0 mg/kg in Healthy subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 mg/kg in Healthy subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TBD mg/kg in FH subjects</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SPC5001</intervention_name>
    <description>3 weekly SC injections</description>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline 0.9%</intervention_name>
    <description>3 weekly SC injections</description>
    <arm_group_label>saline 0.9%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SPC5001</intervention_name>
    <description>3 weekly SC injections</description>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SPC5001</intervention_name>
    <description>3 weekly SC injections</description>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SPC5001</intervention_name>
    <description>3 weekly SC injections</description>
    <arm_group_label>Cohort 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SPC5001</intervention_name>
    <description>3 weekly SC injections</description>
    <arm_group_label>Cohort 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy male or female subjects and subjects with heterozygous Familial
             Hypercholesterolemia

               -  Healthy male or female subjects, age 18 to 65 years, inclusive will be enrolled
                  in Cohorts 1 through 4.

               -  In Cohort 5, male or female subjects with heterozygous Familial
                  Hypercholesterolemia, confirmed through genetic testing, without a history of
                  cardiovascular disease (e.g. coronary artery, peripheral artery or
                  cerebrovascular disease), hypertension or diabetes mellitus age 18-45 years,
                  inclusive, will be enrolled.

          2. BMI of 18-33 kg/m2

          3. Screening hematology, clinical chemistries, coagulation and urinalysis consistent with
             overall good health and the following criteria are met:

               -  LDL ≥.3.24 mmol/L (≥ 100 mg/dL)

               -  Triglycerides (fasted) &lt; 4.5 mmol/L (&lt; 398 mg/dL)

               -  ALT within normal limits for healthy subjects and ALT &lt; 2 x ULN for FH subjects

        Exclusion Criteria:

          1. Any uncontrolled or active major systemic disease including, but not limited to:
             cardiovascular, pulmonary, gastrointestinal, metabolic, urogenital, neurological,
             immunological, psychiatric, or neoplastic disorder with metastatic potential

             - History or presence of malignancy within the past year is an exclusion criterion.
             Subjects who have been successfully treated with no recurrence of basal cell carcinoma
             of the skin or carcinoma in-situ of the cervix may be enrolled.

          2. Active acute or chronic infection, including, but not limited to: upper airway
             infection, urinary tract infection, and skin infection

          3. Use of prescription medication within 14 days prior to the planned first drug
             administration and throughout the study. For the FH subjects statin therapy (and other
             lipid lowering therapies) will be prohibited within 4 weeks prior to the first study
             drug administration.

          4. Use of non-prescription or over-the-counter medications is prohibited within 7 days
             prior to the planned first drug administration and throughout the study. This includes
             all vitamins, herbal supplements, or remedies. An exception can be made for medication
             or supplements that in the opinion of both the investigator and the Sponsor do not
             complicate or compromise the study or interfere with the study objectives.

          5. Positive results on the following Screening laboratory tests: urine or serum pregnancy
             test (women only), alcohol breath test, urine drugs of abuse, hepatitis B surface
             antigen, hepatitis C antibody, and human immunodeficiency virus (HIV) antibody.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Koos Burggraaf, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre for Human Drug Research (CHDR)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre for Huma Drug Research (CHDR)</name>
      <address>
        <city>Leiden</city>
        <zip>2333</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 5, 2011</study_first_submitted>
  <study_first_submitted_qc>May 9, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2011</study_first_posted>
  <last_update_submitted>November 21, 2011</last_update_submitted>
  <last_update_submitted_qc>November 21, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 22, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hypercholesterolemia</keyword>
  <keyword>hyperlipidemia</keyword>
  <keyword>LDL</keyword>
  <keyword>HDL</keyword>
  <keyword>PCSK9</keyword>
  <keyword>LNA-oligonucleotide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

